ArticleOpen forum infectious diseases2019
Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-Positive Organisms
Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 203 citations in OpenAlex.
- Pooled it
- Simulated Target Attainment of Multidose Regimens of Dalbavancin for Prolonged Durations of Therapy.Open forum infectious diseases · 2024Trial
- Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.Open forum infectious diseases · 2024Trial
- Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2023Trial
- Population pharmacokinetics of dalbavancin: external validation, model averaging, and implications for precision dosing in prolonged therapy.Antimicrobial agents and chemotherapy · 2026Article
- A real-world implementation study of a TDM-guided dalbavancin model for bone and joint infections (101 Dalbatians).JAC-antimicrobial resistance · 2026Article
- Real-World Effectiveness of Dalbavancin in Osteomyelitis Without Implantable Devices: A Retrospective Monocentric Study.Antibiotics (Basel, Switzerland) · 2026Article
- Dalbavancin in the Real-World Management of Gram-Positive Infections: A Systematic Review of Randomized and Observational Studies.Microorganisms · 2026Review
- Off-label use of dalbavancin to improve treatment outcomes and reduce health care costs in people who use drugs: A Canadian single-centre quality improvement initiative.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- TDM-Guided Dalbavancin Treatment for ComplexAntibiotics (Basel, Switzerland) · 2026Article
- Real world use of dalbavancin for bone and joint infections: a retrospective case series in adults and children.BMC research notes · 2026Article
- Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?The Journal of antimicrobial chemotherapy · 2026Article
- Predicting prolonged dalbavancin exposure using machine learning: a validated strategy for individualized redosing.Antimicrobial agents and chemotherapy · 2026Article
- A bundle of the top 10 OPAT publications in 2024.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Review
- Article
- Therapeutic Drug Monitoring Versus Fixed-Interval Dosing of Dalbavancin in Implant-Associated Spinal Infections: Grand Round/A Case Study.Therapeutic drug monitoring · 2025Article
- Experience of use of dalbavancin for the treatment of unlicensed indications in a UK tertiary infectious diseases setting.Infection · 2025Article
- Budget Impact and Financial Analysis of Outpatient Dalbavancin in an Urban, Non-Teaching, Community Hospital.Clinical drug investigation · 2025Article
- Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review.Antibiotics (Basel, Switzerland) · 2025Review
- A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?Infectious diseases and therapy · 2025Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteomyelitis is a challenging infection that can involve 4-6 weeks of intravenous (IV) antibiotics. Dalbavancin, approved for acute bacterial skin and skin structure infections, has potent activity against gram-positive pathogens. This study assessed the efficacy and safety of dalbavancin as a 2-dose regimen for osteomyelitis.
methodsThis study was a randomized, open-label, comparator-controlled trial in adults with a first episode of osteomyelitis defined by clinical symptoms, radiologic findings, and elevated C-reactive protein. Patients were randomized 7:1 to dalbavancin (1500 mg IV on days 1 and 8) or standard of care (SOC) for osteomyelitis (oral or IV) per investigator judgment for 4-6 weeks. The primary endpoint was clinical response at day 42, defined as recovery without need for additional antibiotics in the clinically evaluable (CE) population. Clinical response was also assessed at day 21, 6 months, and 1 year.
resultsEighty patients were randomized to dalbavancin (n = 70) or SOC (n = 10). All had baseline debridement;
conclusionsA 2-dose regimen of weekly dalbavancin is effective and well tolerated for the treatment of osteomyelitis in adults. CLINICAL TRIALS REGISTRATION: NCT02685033.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.